{
    "clinical_study": {
        "@rank": "50483", 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of\n      aerosol pentamidine when used as a prophylactic agent in patients who have had at least two\n      or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP)."
        }, 
        "brief_title": "An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n          -  Standard or experimental treatments for an opportunistic infection or neoplasm\n             (including aerosolized or intravenous pentamidine) that develops during the study.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Any standard or experimental treatment for an opportunistic infection or neoplasm\n             that develops during the study.\n\n        Patients must have AIDS with at least one cytologically or histologically proven episode\n        of Pneumocystis carinii pneumonia (PCP).\n\n          -  Patients must be free of acute medical problems.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine (AZT).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection at the time of study\n             entry.\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcus.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Asthma poorly controlled by medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Pentamidine by any route other than aerosolized or intravenous or any other\n             experimental agent for chemoprophylaxis of PCP while on the study (e.g.:\n\n          -  Septra, Fansidar, Dapsone, or eflornithine).\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Transfusion dependency defined as > 1 blood transfusion per month.\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at the time of\n             entry or having either Toxoplasmosis  or cryptococcosis at entry.\n\n          -  Pulmonary Kaposi's sarcoma (KS).\n\n          -  Active substance abuse by patients who cannot comply with study procedures.\n\n          -  Unwilling to sign informed consent.\n\n          -  In the opinion of the investigator cannot cooperate with study procedure.\n\n          -  Asthma poorly controlled by medication.\n\n          -  Patients may not receive pentamidine by any other route than aerosolized or\n             intravenous or any other experimental agent for chemoprophylaxis of PCP while on the\n             study (e.g.:\n\n          -  Septra, Fansidar, Dapsone, or eflornithine).\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Antiretroviral agents, excluding zidovudine (AZT).\n\n          -  Immunomodulating agents.\n\n          -  Corticosteroids.\n\n        Prior Treatment:\n\n        Excluded within 7 days of study entry:\n\n          -  Blood transfusion.\n\n          -  Excluded:\n\n          -  Requiring ongoing active treatments for an opportunistic infection at time of study\n             entry.\n\n        Active substance abuse by patients who cannot comply with study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002030", 
            "org_study_id": "022E", 
            "secondary_id": [
                "87-72B", 
                "88-21"
            ]
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentamidine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Aerosols", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14603"
                }, 
                "name": "Fisons Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002030"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fisons", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1989"
    }, 
    "geocoordinates": {
        "Fisons Corp": "43.161 -77.611"
    }
}